“Diabetic kidney disease could overwhelm our health systems”
Diabetic kidney disease, also known as diabetic nephropathy is one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. The global diabetic nephropathy market is likely to reach $3,145.9 million by 2020 (Persistence Market Research). At such rate, monitoring and management becomes crucial for diabetic patients. Recently, Proteomics International licensed their diabetic kidney disease predictor test (PromarkerD) in the USA and Mexico. During his interaction with BioSpectrum Asia, Dr Richard Lipscombe, CEO of Proteomics International, Australia talks about their star product, plans to launch in other countries and the future of diabetic kidney diagnosis. PromarkerD is a blood test that measures a panel of three proteins found in the circulation. This protein fingerprint is combined with clinical parameters such as age and cholesterol levels and then the PromarkerD algorithm calculates a risk score showing who is likely to get diabetic kidney disease in the near future. In clinical studies, PromarkerD correctly predicted 86 per ent of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. The test is yet to be evaluated in people with pre-diabetes, however, clinical studies published by others have suggested kidney disease may begin at the pre-diabetes stage, hence PromarkerD may be useful for this group too. The problem with managing kidney disease in Australia is no different from other parts of the world – with one-third of all adults with diabetes having chronic kidney disease. The risk is that health systems will soon be overwhelmed by the numbers requiring dialysis or a kidney transplant.
Dr Richard Lipscombe,CEO, Proteomics International, Australia